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Abstract 
Although important advances in the management of breast cancer (BC) have been recently accomplished, it still con-
stitutes the leading cause of cancer death in women worldwide. BC is a heterogeneous and complex disease, making 
clinical prediction of outcome a very challenging task. In recent years, gene expression profiling emerged as a tool to 
assist in clinical decision, enabling the identification of genetic signatures that better predict prognosis and response 
to therapy. Nevertheless, translation to routine practice has been limited by economical and technical reasons and, 
thus, novel biomarkers, especially those requiring non-invasive or minimally invasive collection procedures, while 
retaining high sensitivity and specificity might represent a significant development in this field. An increasing amount 
of evidence demonstrates that non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long noncoding 
RNAs (lncRNAs), are aberrantly expressed in several cancers, including BC. miRNAs are of particular interest as new, 
easily accessible, cost-effective and non-invasive tools for precise management of BC patients because they circulate 
in bodily fluids (e.g., serum and plasma) in a very stable manner, enabling BC assessment and monitoring through 
liquid biopsies. This review focus on how ncRNAs have the potential to answer present clinical needs in the personal-
ized management of patients with BC and comprehensively describes the state of the art on the role of ncRNAs in the 
diagnosis, prognosis and prediction of response to therapy in BC.
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Background
Breast cancer (BC) is one of the most common cancers 
with more than 1,300,000 cases diagnosed and 450,000 
deaths occurring each year, worldwide [1]. Due to earlier 
diagnosis and implementation of adjuvant chemo- and 
hormone-therapies (HT), BC mortality has been declin-
ing, although it remains the most common cause of can-
cer-related death among women [2]. At present, most 
patients are diagnosed at localized disease stage, but 
20–85 % of all patients will eventually develop recurrent 
and/or metastatic disease [3].
BC is intrinsically heterogeneous, representing a spec-
trum of diseases with distinct morphology, molecular 
traits, prognosis, and therapeutic options. On the basis 
of gene expression, BC cases are often classified into 
one of five intrinsic subtypes [4]. The large majority of 
estrogen receptor (ER) and/or progesterone receptor 
(PR)-positive (+) tumors are of the luminal subtypes that 
typically express luminal cytokeratins (CK) 8 and 18 [5]. 
These tumors are further subdivided into Luminal A and 
Luminal B, according to the expression levels of Ki67, a 
nuclear protein that is associated with cellular prolifera-
tion. The ER and PR-negative (−) tumors are divided into 
three subtypes: the basal-like subtype, characterized by 
the expression of CK 5/6 and CK17; the human epider-
mal growth factor receptor 2 (HER2)-enriched subtype, 
which are positive for HER2; and the “normal-like” sub-
type, characterized by a similar gene expression pattern 
as the normal breast. This last subtype remains enigmatic 
as to whether it represents a separate subtype or a techni-
cal artifact introduced by the contamination of cancerous 
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BC clinical decisions are based on routine assays for 
ER, PR and HER2, as well as Ki67 [6]. The molecular 
phenotype of the tumor is indicative of the most suit-
able treatment, i.e., either endocrine therapy (ET) in 
hormone receptor positive or HER-targeted therapy in 
HER2+ tumors [7]. Globally, ER− tumors have a poorer 
prognosis in the first few years after diagnosis, but after 
5–10  years, ER+ tumors demonstrate the poorest out-
come [8]. However, not all ER+ BCs behave similarly, and 
the studies conducted in recent years show that luminal 
A and B BCs should be perceived as distinct entities [9]. 
Luminal A subtype has been shown to exhibit good clini-
cal outcomes with ET whereas the pattern of mortality 
rates associated with the luminal B tumors is similar to 
those of the non-luminal subtypes [10]. However, Lumi-
nal A, the most frequently occurring BC subtype, is also 
the most heterogeneous subtype, both molecularly and 
clinically [11]. Indeed, ER expression itself fails to predict 
which ER+ tumors will respond or be resistant to differ-
ent modalities of ET, and resistance has been reported in 
30 % of ER+ BCs [12].
Due to molecular heterogeneity, clinical decisions 
based solely upon histopathologic analysis or one or 
small numbers of genes or their coding proteins in the 
tumor tissue are limited. Moreover, the widespread use 
of gene-expression profiling using commercially avail-
able molecular signatures for the examination of multiple 
expressed genes is also of limited application, primarily 
due to the cost and to reproducibility issues [13, 14].
Recently, several studies have reported on the associa-
tion between microRNAs (miRNAs) and BC, suggesting 
its usefulness as disease biomarkers. Interestingly, miRNA 
detection in bodily fluids appear to have superior accu-
racy than messenger RNA (mRNA) profiling because of 
their high tissue-specificity, stability, and aberrant expres-
sion in different tumor types [15]. miRNAs have the addi-
tional advantage of being long-lived in vivo [16] and very 
stable in vitro [17, 18], which might be critical in a clini-
cal setting. Indeed, tumor cells were suggested to release 
miRNAs stabilized by their association with RNA-binding 
proteins and by their incorporation into microvesicles 
[19, 20]. The emergence of non-coding RNA (ncRNAs) as 
biomarkers may add robustness to the current molecular 
classification of human BC, with the potential for improv-
ing diagnosis and monitoring of BC. Thus, in this review, 
we will focus on ncRNAs as potential diagnostic, predic-
tive and prognostic biomarkers for BC management.
Evidence acquisition
For the selection of bibliography, PubMed publications 
on BC were searched using the keywords breast can-
cer, noncoding RNAs and microRNAs. References of all 
articles were also examined for additional potentially 
relevant studies. The criteria for article selection were: 
written in English, central theme based on ncRNAs and 
BC. Original reports were selected based on the detail of 
analysis, mechanistic support of data, novelty, and poten-
tial clinical usefulness of the findings.
Non‑coding RNAS
It is currently acknowledged that at least 98  % of the 
mammalian genomes and other complex organisms 
are transcribed into ncRNAs [21]. In fact, ncRNAs that 
were previously thought to be “transcription noise”, are 
believed to be a hidden layer of internal signals that con-
trol various levels of gene expression, playing a significant 
role in cell homeostasis and its deregulation is involved 
in the development of several human diseases. The family 
of ncRNAs, in addition to the well knows transfer RNAs 
(tRNAs), ribosomal RNAs (rRNAs), and small nucleolar 
RNAs (snoRNAs), includes the recently discovered long 
noncoding RNAs (lncRNAs) and miRNAs.
Transfer RNA (tRNA)
Transfer RNAs are small ncRNA transcripts, typically 
with 76–90 nucleotides (nt) in length, that serve as physi-
cal link between mRNA and the aminoacid sequence 
of proteins [22]. In 2009, Pavon-Eternod [23] analyzed 
genome-wide tRNA expression and found that tRNAs 
were increased in BC compared to normal breast tissues. 
Their results also suggested a functional consequence of 
tRNA over-expression in tumor cells, which seems to be 
selective and may increase the translational efficiency of 
genes relevant to cancer development and progression.
Recent studies indicated that precise cleavage of tRNAs 
generate active products [24]. Indeed, high levels of 
tRNA-derived miRNas or of tRNA-derived molecules 
termed 5′tRNA halves are likely to be a manifestation 
of tRNA over-expression. Park [25] reported that miR-
1280—a tRNA-derived fragment was significantly 
up-regulated in blood of BC patients, particularly in 
metastatic BC patients, compared to healthy subjects 
and decreased significantly after systemic treatment in 
patients who responded to treatment, while increasing 
in the blood of patients with non-responding tumors. 
Moreover, BC is associated with expression deregula-
tion—either increase or decrease—in the circulating 
levels of 5′tRNA halves derived from specific tRNA iso-
acceptors [26], and changes in circulating 5′tRNA halves 
were associated with specific tumor features, such as ER/
PR/HER2-status, raising the possibility of a causal con-
nection with some aspects of breast carcinogenesis.
Long noncoding RNAs (lncRNAs)
LncRNAs are ncRNA molecules usually longer than 
200 nts that do not fit into known classes of small or 
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structural RNAs, and that may function as either primary 
or spliced transcripts [27]. LncRNAs may be transcribed 
from various genomic locations, as well as in their own 
stand-alone position in the genome—long intergenic 
non-coding RNAs (lincRNAs) [28]. LncRNAs have 
gained widespread attention in recent years as a poten-
tially new and crucial layer of biological regulation, con-
trolling cell cycle, apoptosis and differentiation by acting 
as protein-DNA or protein–protein scaffolds, miRNA 
sponges, protein decoys, and regulators of translation 
[29].
LncRNAs in breast cancer
LncRNAs were already found to be differentially 
expressed in BC tissues compared to normal breast tis-
sues and recent studies have demonstrated their key reg-
ulatory role in gene expression and BC biology through 
diverse mechanisms [30].
Diagnostic biomarkers
Expression levels of lncRNAs have been investigated in 
BC tissues compared to normal tissues indicating that 
some may be potential biomarkers for BC diagnosis. 
Ding et  al. found that lincRNA-BC2 and lincRNA-BC5 
were consistently up-regulated (more than twofold) in 
BC samples, whereas lincRNA-BC4 and lincRNA-BC8 
were down-regulated [31]. Moreover, lincRNA-BC4 
expression was significantly lower in grade III BC, and 
lincRNA-BC5 expression was significantly higher in 
grade III, whereas lincRNA-BC2′ expression signifi-
cantly associated with lymph node metastasis (LNM). 
Remarkably, lncRNAs’ expression was also found to be 
highly associated with BC subtype classification [32]. 
Later studies have also demonstrated that lncRNAs 
are amenable for detection in bodily fluids. For exam-
ple, the serum expression levels of circulating lncRNA 
RP11-445H22.4 were found significantly increased in BC 
patients, identifying BC cases with 92 % sensitivity and 
74 % specificity [33].
Prognostic biomarkers
In addition to lncRNAs potential use as diagnostic bio-
markers, they have been suggested as valuable prog-
nostic biomarkers. Zhao and co-workers identified a 
set of lncRNAs that distinguished low-risk from high-
risk BC patients [34]. Patients with significantly higher 
LINC00324 expression and lower PTPRG antisense RNA 
1 (PTPRG-AS1) and small nucleolar RNA host gene 17 
(SNHG17) expression showed longer overall survival 
(OS). In another study, high SPRY4 intronic transcript 1 
(SPRY4-IT1) expression levels were also associated with 
poorer prognosis, specifically shorter disease-free sur-
vival (DFS) [35].
HOX transcript antisense RNA (HOTAIR) overexpres-
sion in BC tissues has been associated with higher inva-
sion and metastatic capacities, and suggested as an OS 
and progression free-survival (PFS) biomarker [36]. Spe-
cifically, in ER+ BC patients, HOTAIR expression was 
shown to independently predict the risk of metastasis 
[37]. Similarly, metastasis-associated lung adenocarci-
noma transcript 1’s (MALAT1) upregulation was found 
in primary BC and its levels were further increased in the 
respective metastases [38]. Conversely, BC040587 [39], 
neuroblastoma associated transcript 1 (NBAT1) [40] and 
eosinophil granule ontogeny transcript (EGOT) [41] were 
found downregulated in BC samples and associated with 
poor prognosis. Furthermore, LINC00472 high expres-
sion levels in BC tissues associated with less aggressive 
behavior and more favorable outcome [42].
Predictive biomarkers
LncRNAs have been suggested as valuable predictive bio-
markers. Indeed, BC anti-estrogen resistance 4 (BCAR4) 
overexpression has been shown to predict tamoxifen 
resistance [43]. On the other hand, lincRNAs LINC00160 
and LINC01016 were both found highly overexpressed in 
ER+ tumors compared to ER− tumors and normal tissues, 
being significantly associated with longer OS of luminal 
A BC [44]. Interestingly, these lincRNAs may identify 
patients that respond to ET, functioning as robust predic-
tive biomarkers for ER activity.
Besides ET resistance, progression or recurrence due 
to resistance to trastuzumab or other commonly used 
therapeutic approaches, such as chemotherapy and 
radiotherapy, also constitute a significant clinical chal-
lenge. LncRNA activated by TGF-β (ATB) has been asso-
ciated with trastuzumab resistance in BC patients [45]. 
Conversely, lncRNA colon cancer associated transcript 
2 (CCAT2) overexpression identified a subset of BC 
patients that might not benefit from cyclophosphamide, 
methotrexate and fluorouracil (CMF) based adjuvant 
chemotherapy [46]. Finally, Chen et al. [47] demonstrated 
that overexpression of lincRNA Regulator of Reprogram-
ming (ROR) is associated chemotherapy tolerance.
microRNAs (miRNAs)
miRNAs are endogenous, small non-coding single-
stranded RNAs with an approximate length of 22  nt, 
encoded by various genomic regions in either sense or 
antisense orientation [48]. miRNAs are critical for a wide 
range of biological processes exerting a finely tuned regu-
lation of gene expression at posttranscriptional level [49].
miRNAs in breast cancer
miRNA dysregulation in cancer was first reported in 
2002 [50]. Since then, the emergence of miRNAs has 
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been one of the defining developments in cancer biology 
with several studies demonstrating a differential miRNA 
expression profile and global miRNA downregulation 
in human malignancies compared with paired normal 
tissues. Indeed, aberrant miRNA expression in human 
tumors is not just a casual association, as it exerts a 
causal role at different steps of the tumorigenic process. 
Some of the miRNAs that will be mentioned here have 
already been associated with several hallmarks of cancer 
[3, 51, 52] (Fig. 1).
miRNAs might be classified into oncogenic miRNAs 
(oncomiRs) or tumor suppressor miRNAs, depend-
ing on their targets. OncomiRs act by repressing the 
expression of tumor suppressor genes and are frequently 
upregulated in cancer. Tumor suppressor miRNAs act by 
targeting oncogenes and are frequently downregulated 
in cancer. However, this miRNA categorization may be 
inaccurate, as many studies have shown that miRNAs 
may present a dual function, with oncogenic or tumor 
suppressive properties based on tumor type and cellu-
lar context [53]. Furthermore, some miRNAs are con-
sistently up- or down-regulated in tumor specimens, 
whereas other, such as miR-221 and miR-10b, exhibit a 
more irregular pattern of expression [54]. MiR-10b was 
found downregulated in all BCs from metastasis-free 
patients, but elevated miR-10b levels were found in pri-
mary tumors from patients harboring metastasis, sug-
gesting that miR-10b might be differentially deregulated 
along tumor progression [55]. Volinia et al. [56] studied 
this change in miRNA expression along cancer progres-
sion and found that let-7d, miR-210 and miR-221 were 
downregulated in the ductal carcinoma in situ compared 
to normal breast tissue, but it was found to be upregu-
lated in the transition to invasive carcinoma, featuring an 
expression reversal along the cancer progression path.
Diagnostic biomarkers
Each tumor type has a distinct miRNA signature that dis-
tinguishes it from normal tissues and other cancer types 
[15]. In 2005, Iorio et al. [57] identified a 13-miRNA sig-
nature that could discriminate BC from normal breast 
tissues with perfect accuracy. Among the differentially 
expressed miRNAs, the most consistently dysregulated 
were miR-125b and miR-145 (downregulated), and miR-
21 (up-regulated). Since then, many studies have looked 
at specific miRNAs dysregulated in BC with a diagnostic 
purpose.
In addition to studies of miRNA expression patterns in 
tissues, expression profiling studies of miRNAs in bodily 
fluids have been performed, to investigate whether bod-
ily fluids could be used to differentiate BC patients from 
healthy individuals. In this context, Heneghan et al. [58] 
found significantly higher levels of miR-195 and let-7a 
in the blood of BC patients compared to healthy con-
trols, detecting BC with high sensitivity and specificity. 
Several studies have also highlighted differences in the 
profiles of serum and plasma miRNAs in cancer com-
pared to healthy individuals. MiR-222, for example, was 
significantly increased in the serum of BC patients [59], 
while higher miR-205 levels have been found in the sera 
of healthy individuals compared to BC patients [60]. Fur-
thermore, Zhao et al. found that miR-195 was downregu-
lated in the plasma of BC patients compared to healthy 
subjects [61].
miRNA profiles show better diagnostic performance 
as well as increased sensitivity than individual miRNAs, 
for BC detection. Hu et al. identified a 4-miRNA signa-
ture with increased concentrations in the serum of BC 
patients that could distinguish BC patients from healthy 
individuals with 92.1 and 93.4  % sensitivity and speci-
ficity, respectively [62]. More recently, Zhang and co-
workers have found a 3-miRNA signature in serum as a 
diagnostic biomarker for non-invasive early detection of 
BC [63], whereas Ng et al. reported that the combination 
of miR-145 and miR-451 levels in plasma may discrimi-
nate normal individuals from BC patients, both at early 
and advanced stages of disease [64]. Finally, Cuk et  al. 
have also found a panel of deregulated plasma miRNAs 
that were elevated in women with benign and stage I or 
II BC, that might be attractive candidates for early BC 
detection [65].
Table  1 summarizes these and others non-circulating 
and circulating miRNAs already described and validated 
in large cohorts for BC diagnosis.
Despite the identification of non-circulating and circu-
lating miRNAs aberrantly expressed in BC, discrepancies 
remain among the different miRNA signatures reported, 
probably due to differences in clinicopathological vari-
ables and the intrinsic heterogeneity of BC. Therefore, 
an attempt has been made to develop miRNA signatures 
that might reflect distinct histopathological features of 
BC.
Indeed, altered miRNAs levels that predict ER, PR 
and HER2 receptor status have already been identified 
(Table  2). Lowery et  al. identified a 15-miRNA predic-
tive signature corresponding to the expression of ER, PR, 
and HER2 receptor status [74]. Recently, Cizeron-Clairac 
and co-workers found that 20 miRNAs were significantly 
deregulated in ER+ compared to ER− BCs [75]. Up-regu-
lation of miR-1244 and downregulation of miR-30e were 
specific of ER− tumors, whereas downregulation of miR-
18a, miR-18b and miR-654-3p and up-regulation of miR-
342-5p and miR-190b were specific of ER+ tumors.
Circulating miRNAs were also found to correlate with 
ER, PR and HER2 status in several studies. For example, 
higher levels of circulating miR-182 [77], miR-21 and 
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miR-10b [58] have been correlated with ER/PR− tumors. 
Furthermore, miR-155 expression levels were higher in 
sera of women with hormone-sensitive BCs [79]. Moreo-
ver, higher levels of circulating miR-375 were associated 
with ER/PR− and HER2+ tumors, whereas higher levels 
of circulating miR-122 associated with HER2− tumors 
[78].
Several specific miRNA expression profiles have also 
been associated with BC molecular subtypes. Iorio et al. 
identified a distinct miRNA signature in luminal BC, with 
overexpression of miR-191 and miR-26 and downregu-
lation of miR-206 [57]. Likewise, miRNAs might differ-
entiate between basal and luminal tumor subtypes in an 
independent data set [81]. In an attempt to capture the 
heterogeneity of Luminal A and Luminal B BCs, Endo 
et al. compared the expression profiles of miRNAs in ER+ 
tissues between ERhigh/Ki67low tumors and ERlow/Ki67high 
tumors [82]. They found that six miRNAs (let-7a, miR-
15a, miR-26a, miR-34a, miR-193b and miR-342-3p) were 
upregulated and a single miRNA was downregulated 
(miR-1290) in ERhigh/Ki67low tumors [82].
Prognostic biomarkers
miRNAs have been correlated with clinical and patho-
logical features that associate with prognosis in differ-
ent tumor types and subgroups of BC patients [83, 84]. 
The search for prognostic biomarkers is a continuous and 
fundamental work in progress, since patients at higher 
risk may require differential therapeutic interventions.
One of the main reasons for the BC associated mortal-
ity is metastization [85], a complex process that allows 
the primary tumor cells to spread to the neighboring as 
Fig. 1 miRNAs as key regulators of BC hallmarks. Expression of miRNAs (↑up-regulated and ↓ down-regulated) grouped according to their function 
in the hallmarks of breast cancer: circulating miRNAs (red) and non-circulating miRNAs with prognostic (bold) and predictive (underlined) value. miR 
microRNA; fam family
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well as to distant parts of the organism. miRNAs appear 
to be involved in the phenotypic changes associated with 
metastasis formation, such as epithelial-mesenchymal 
transition, as well as with the presence of circulating 
tumor cells, which correlate with metastatic spread [86]. 
miRNAs may act either as promotors of BC metastasis or 
as metastasis suppressors. Metastasis promoters include 
miR-9 [87], miR-10b [55, 88], miR-21 [89], miR-29a [90], 
miR-155 [91], miR-520c [92], miR-373 [88, 92], miR-214 
[93], miR-301 [94] and miR-548j [95], whereas metas-
tasis suppressors include miR-17/20 [96], miR-126 [97], 
miR-193b [98], miR-206 [99], miR-335 [100], miR-448 
[101], miR-601 [102], miR-138 [103], miR-515-5p [104], 
miR-203 [105], miR-200 family and miR-205 [106]. These 
specific miRNAs might serve as valuable biomarkers 
Table 1 Non-circulating and circulating miRNAs for BC diagnosis
↑ Up-regulated ↓ Down-regulated
N normal, SdM serum-direct multiplex
miRNAs Sample Validation  
techniques
Samples size Sensitivity Specificity AUC Refs
Non-circulating 
miRNAs
↑miR-23a BC tissues qRT-PCR 76BC vs. 36 benign 
vs. 36 N
0.829 0.100 0.915 [66]
↑miR-155, -21, -184, 
-518b, -572, -601, 
-622 ↓miR-125b




SYBR Green qRT-PCR 56BC vs. 9 N
60BC vs. 11 N
– – – [68]
Circulating miRNAs ↑miR-222 Serum qRT-PCR 50BC vs. 50 N 0.74 0.60 0.671 [59]
↑miR-16, -25, -222, 
-324-3p
TaqMan qRT-PCR 76BC vs. 76 N 0.921 0.934 0.928 [62]
↑miR-145, -155, -382 qRT-PCR 61BC vs. 10 N 0.976 0.100 0.988 [69]
↓miR-205 qRT-PCR 58BC vs. 93 N 0.862 0.828 0.84 [60]
↑miR-199ª, -29c, -424 SdM-RT-PCR 76BC vs. 52 N 0.776 0.846 0.901 [63]
↑miR-92a, miR-133a qRT-PCR 132BC vs. 101 N – – 0.91 [70]
↓miR-200c Whole blood qRT-PCR 57BC vs. 20 N 0.90 0.702 0.79 [71]




TaqMan qRT-PCR 120BC vs. 60 N 0.800 0.720 0.81 [65]
↓miR-195 SYBR Green qRT-PCR 210BC vs. 102 N 0.69 0.892 0.859 [61]
↑miR-16, -148a, -19b, 
-22a ↓Let-7d, let-7i, 
miR-103, -107
qRT-PCR 108BC vs. 88 N 0.91 0.49 0.81 [72]
↑miR-505–5p  
↑miR- 96–5p
qRT-PCR 114BC vs. 116 N – – 0.72
0.72
[73]
Table 2 miRNAs which increased expression predicts 
for ER, PR and HER2 receptor status in BC
Circulating miRNAS are represented in italic
Refs.
ER status
ER+ miR-342, -217, -190b, -218, -342-5p [74–76]
ER− miR-299-3p, -190, -135b, -182, -21, -30e, 
-1244, -10b, -375
[58, 74, 75, 77, 78]
PR status
PR+ miR-520f-520c, -377, -155 [74, 79]




HER2+ miR-520d, -376b, -146a-5p, -375 [74, 80]
HER2− miR-181c, -122 [74, 78]
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for predicting metastasis and tumor recurrence, which 
determine the unfavorable prognosis of BC patients. All 
these miRNAs were validated in tumor tissues and/or 
bodily fluids from BC patients and are depicted in Fig. 2.
miRNAs have also been associated with other clini-
cal and pathological features that influence BC patients’ 
prognosis. miR-21, aside from being a driver of metas-
tasis, has been known to create a pro-tumorigenic envi-
ronment by targeting numerous tumor suppressor genes, 
and its overexpression was correlated with advanced 
tumor stage and poor OS and DFS in BC patients [107, 
108]. Several studies have independently associated miR-
210 with BC development and its expression levels were 
correlated with tumor aggressiveness and poor prognosis 
[109, 110]. Moreover, some miRNAs have been associ-
ated with a good prognosis, such as the miR-30 family, 
that has been identified as an individual favorable prog-
nostic marker in several studies [111–113]. Other miR-
NAs, particularly downregulation of the miR-200 family, 
have also been associated with BC stem cells [114], one 
of the main obstacles for effective treatment of BC [115].
Some studies have focused on particular subtypes of 
BC. Bailey et  al. evaluated miRNAs expression in ER+ 
BC tissues and found that a cluster comprising let-7c and 
miR-125b was uniformly low in luminal B and lost in a 
subset of luminal A patients with worse OS, indicating its 
potential as biomarker of good outcome in ER+ luminal 
A BC patients [116]. Gasparini and co-workers identi-
fied a 4-microRNA signature in triple negative BC that 
allowed for the stratification of those patients into high- 
and low-risk groups [117]. Up-regulation of miR-493 and 
miR-155 correlated with better patient outcome, whereas 
miR-30e and miR-27a downregulation correlated with 
worse outcome [117].
Interestingly, some miRNAs may differentially influ-
ence outcome depending on the characteristics of the 
tumors. Tuomarila et  al. reported that high miR-200c 
expression independently predicted poor OS in patients 
with PR− tumors, whereas low expression independently 
predicted poor OS in patients with PR+ tumors [118].
These and other miRNA signatures or single miRNAs 
that have been associated with prognosis are summarized 
in Table 3.
Predictive biomarkers
The role of miRNAs as potential predictive biomark-
ers is also a field of growing interest. When investigat-
ing the regulation of miRNAs expression by antiestrogen 
Fig. 2 miRNAs and breast cancer metastasis. miRNAs are crucial in metastatic spreading, acting either as oncogenes, typically up-regulated, or as 
tumor suppressor genes, typically down-regulated. Circulating (red), non-circulating miRNAs and examples of targets. miR microRNA, CD cluster of 
differentiation, ZEB Zinc Finger E-Box binding homeobox 1, MMPs matrix metalloproteinases, VIM vimentin, CDH1 cadherin 1
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Table 3 miRNA panels or single miRNAs proposed with a prognostic aim
↑ Incresead; ↓ Decreased
RFS relapse-free survival, TNM TNM classification of malignant tumours, MFS metastasis-free survival, LR local recurrence, DSS disease-specific survival
miRNA Biological sample Consequences Refs.




Let-7b, miR-205 ↑RFS, OS [122]
miR-342-5p [123]
miR-497 ↓TNM, LNM [124]
miR-133a ↑RFS [125]
miR-30 family ↑ OS, RFS, DFS
↓Metastasis
[111–113]
miR-206 ↑OS ↓TNM, LNM [126]
miR-601 ↓Metastasis ↑MFS [102]
miR-124 ↑OS ↓TNM, LNM [127]
miR-138 ↓TNM, LNM [103]
miR-190b ↑MFS, OS [75]
miR-200b ↓LNM [128]




TNBC tissues ↑DFS, OS [131]
miR-155 -493 ↑OS [117]
let-7c, miR-99a, -125b Luminal A BC tissues ↑OS [116]
miRNAs associated with negative outcome miR-21 Tumor tissues ↑Grade, TNM, LNM, metastasis
↓DFS, RFS, OS
[107, 108]
miR-210 ↓OS, RFS, DFS, MFS ↑Grade [109]
miR-23a ↓RFS [66]
miR-423 ↑Metastasis [132]
miR-9 ↑Grade, metastasis, LR [87]
miR-187 ↓DSS, RFS [133]
miR-155 ↑TNM, grade, LNM ↓OS [134]
miR-221/222 ↓MFS [135]
miR-421, -486, -503, -720, -1303 ↓MFS [136]
miR-375 ↑LR [137]
miR-548 family ↑LNM ↓MFS [95]
miR-146a-5p ↓OS [80]
miR-27b-3p TNBC tissues ↑Metastasis ↓DSS [138]
miR-93 ↑LNM, TNM, grade, Ki-67 [139]
miR-21, -210, -221 ↓DFS, OS [140]
miR-34b [141]
miR-18b, -103, -107, -652 TNBC patients serum ↓OS, RFS. [142]
miR-200b BC patients plasma ↓PFS, OS [86]
miR-202 BC patients serum ↓OS [143]
miR-10b-5p ↑TNM, grade, LNM [144]
miR-122 ↓MFS, RFS [78]
miR-10b, -34a, -155 ↑Metastasis [145]
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therapies in human BC specimens using the initial biopsy 
and comparing it with the surgery specimen after neo-
adjuvant ET, Maillot and co-workers [146] noticed that 
some miRNAs that were previously shown overexpressed 
in tamoxifen-resistant cell lines were up-regulated fol-
lowing ET. These results highlight the utility of consider-
ing miRNA expression in understanding ET resistance 
in BC. Other studies have searched for miRNAs able to 
predict therapeutic response of BC patients to ET. For 
instance, Rodriguez-Gonzalez and colleagues [147] have 
found that miR-30c independently predicted clinical ben-
efit of tamoxifen therapy in patients with advanced BC. 
On the other hand, Rothe et al. [110] found that miR-210 
high level expressions were associated with a higher risk 
of recurrence in tamoxifen treated patients.
In addition to ET, miRNAs have been involved in 
responsiveness to other therapies. For instance, high 
circulating levels of miR-210 have been associated with 
resistance to anti-HER2 therapy using trastuzumab [148] 
and miR-100 expression has been positively correlated 
with sensitivity to chemotherapy using paclitaxel [119]. 
The potential role of miRNAs in the prediction of the 
response to these and other therapies, such as radiother-
apy, are summarized in Table 4.
Several clinical trials, summarized in Table 5, are cur-
rently ongoing to address the role of miRNAs in diag-
nosis, prognosis and prediction of response to therapy, 
aiming at the translation of current knowledge on miR-
NAs in BC into clinical practice.
Conclusion
BC is a very heterogeneous disease, and several biological 
features are routinely used for diagnostic, prognostic and 
predictive purposes, including histological grade, lymph 
node status, hormone receptor status, and HER2 status. 
These factors have been associated with BC patient’s sur-
vival and clinical outcome following treatment. Never-
theless, some patients with similar combination of those 
features follow different clinical paths, demonstrating 
that the capacity of determining prognosis and predict-
ing therapeutic outcome in BC patients remains limited. 
Several mRNA-based tests are currently available with 
the aim of improving BC prognostication, but its use 
in clinical practice is still limited. New biomarkers are 
therefore needed to assist in improving BC patient prog-
nostication and monitoring, allowing for a more precise 
definition of the therapeutic and follow-up strategy in an 
individual basis.
Based on the studies cited in this review, it is remark-
able that ncRNAs are adding an extra dimension to the 
understanding of BC biology. miRNAs, in particular, are 
emerging as promising biomarkers for BC diagnosis (e.g. 
miR-155 and miR-195), prognosis (e.g. miR-29b and miR-
30 family) and prediction of response to therapy (e.g. miR-
30c and miR-221). It should be emphasized that miRNAs 
are easily accessible, affordable, non-invasive tools for per-
sonalized management of BC patients, since they circulate 
stably in bodily fluids. These features allow miRNAs to 
respond to current clinical needs and provide the oppor-
tunity to bypass the problems associated with tumor tissue 
biopsy. Although some lncRNAs have also shown potential 
to serve as BC biomarkers, the stability and origin of cir-
culating lncRNAs remain largely unknown, and additional 
studies are required to support a definitive clinical applica-
tion. Regarding tRNAs, many questions also remain unan-
swered, such as the origin and its physiological role.
When reviewing the data from several studies, wide-
spread inconsistencies across them are found. The cause 
might be attributable to differences in sample type, with 
some studies using plasma or serum and other using 
whole blood, differences in technology platforms used 
for miRNA profiling, such as next-generation sequenc-
ing (NGS) or real time reverse transcription polymerase 
chain reaction, differences in the choice of pre- or—post-
operative samples, as well as from the choice of different 
genes for data normalization. These discrepancies among 
reported signatures highlight the need to standardize 
experimental conditions for circulating miRNAs studies, 
as well as the need to validate these findings in additional 
independent cohorts as well as preclinical/clinical veri-
fication studies, before the clinical utility of circulating 
miRNAs may be established.
In conclusion, the emergence of ncRNA classes as 
possible BC biomarkers, mainly miRNAs, shows great 
potential to foster precision medicine in BC, although its 
application in clinical routine is still a long term goal.
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Table 4 miRNAs involved in therapeutic response (sensitivity/resistance) in BC
CCNB1 cyclin B1, EZH2 enhancer of zeste homolog 2, EGFR epidermal growth factor receptor, CDKN1B cyclin-dependent kinase inhibitor 1B, PTEN phosphatase and 
tensin homolog, RB1 retinoblastoma 1, SOCS6 suppressor of cytokine signaling 6, FOXF2 forkhead box F2, BBC3 BCL2 binding component 3, COL2A1 collagen type II 
alpha 1, ERBB2 Erb-B2 receptor tyrosine kinase 2, BCL2L11 Bcl-2-like protein 11, MRP1 multidrug resistance-associated protein 1, ABCC1 ATP binding cassette subfamily 
C member 1, BMI1 BMI1 polycomb ring finger oncogene, ABCC5 ATP binding cassette subfamily C member 5, MTOR mechanistic target of rapamycin, IKBKB IκB kinase 
β, FBXO11 F-box protein 11, BAK1 BCL2 antagonist/killer 1, E3F3 E2F transcription factor 3, FOXO3a Forkhead box O3a, RAD51 RAD51 recombinase, FEC 5-florouracil, 
epirubucin and cyclophosphamide
Therapies Role in response miRNA Putative targets Agent Biological samples Refs.
Hormone therapy
Antiestrogens Sensitivity miR-342 CCNB1 Tamoxifen Cell lines and tumor 
tissues
[149]
miR-26a EZH2 Tumor tissues [150]
miR-30c EGFR [147]
miR-10, -126 – [151]
Resistance miR-221/222 CDKN1B Tamoxifen, fulvestrant Tumor tissues and cell 
lines
[152, 153]




miR-210 – Tumor tissues [110]
miR-301 FOXF2, BBC3, PTEN, 
COL2A1
Tumor tissues, cell lines 
and xenografts
[94]
Aromatase inhibitors Sensitivity miR-125b let-7c ERBB2 Letrozole, anastrozole Tumor tissues and cell 
lines
[116]
Resistance miR-181a BCL2L11 Letrozole Cell lines, xenografts 
and tumor tissues
[155]
Antibodies Sensitivity miR-210 – Trastuzumab Cell lines and plasma [148]
Resistance miR-21 PTEN Trastuzumab Cell lines, xenograft and 
tumor tissues
[156]





miR-128 BMI1, ABCC5 Doxorubicin, Paclitaxel Cell lines, xenografts 
and tumor tissues
[121]
miR-100 MTOR Paclitaxel Cell lines, xenografts 
and luminal tumor 
tissues
[119]
miR-16 IKBKB Cell lines and tumor 
tissues
[160]
miR-621 FBXO11 Paclitaxel + Carboplatin Cell lines, xenografts 
and tumor tissues
[161]
Resistance miR-125b BAK1, E2F3 FEC Cell lines, tumor tissues 
and serum
[162]
miR-141 − Taxane, Anthracyclines Cell lines and tumor 
tissues
[163]
miR-221 CDKN1B Plasma [164]
miR-155 FOXO3a Paclitaxel, VP-16, Doxo-
rubicin
Cell lines and tumor 
tissues
[165]
Radiotherapy Sensitivity miR-155 RAD51 – Cell lines and TNBC 
tissues
[166]
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